Literature DB >> 12417685

Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice.

Rebecca J Ralph-Williams1, Virginia Lehmann-Masten, Veronica Otero-Corchon, Malcolm J Low, Mark A Geyer.   

Abstract

Stimulation of the dopamine (DA) system disrupts prepulse inhibition (PPI) of the acoustic startle response. On the basis of rat studies, it appeared that DA D2 receptors (D2Rs) rather than D1 receptors (D1Rs) regulate PPI, albeit possibly in synergism with D1Rs. To characterize the DA receptor modulation of PPI in another species, we tested DA D1R and D2R mutant mice with direct and indirect DA agonists and with the glutamate receptor antagonist, dizocilpine (MK-801). Neither the mixed D1/D2 agonist apomorphine (5 mg/kg) nor the more selective D1-like agonist SKF82958 (0.3 mg/kg) altered PPI in D1R knock-out mice, although both compounds disrupted PPI in D2R mutant and wild-type mice, suggesting that the D1R alone might modulate PPI in mice. However, amphetamine (10 mg/kg) significantly lowered PPI in each genotype of D1R mice, suggesting that the D1R is not necessary for the PPI-disruptive effect of the indirect agonist in mice. As reported previously, amphetamine (10 mg/kg) failed to disrupt PPI in D2R knock-out mice, supporting a unique role of the D2R in the modulation of PPI. Dizocilpine (0.3 mg/kg) induced similar PPI deficits in D1R and D2R mutant mice, confirming that the influences of the NMDA receptor on PPI are independent of D1Rs and D2Rs in rodents. Thus, both D1Rs and D2Rs modulate aspects of PPI in mice in a manner that differs from dopaminergic modulation in rats. These findings emphasize that further cross-species comparisons of the pharmacology of PPI are essential to understand the relevance of rodent PPI studies to the deficits in PPI observed in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417685      PMCID: PMC6758013     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  59 in total

1.  Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor.

Authors:  Emilio Fernandez-Espejo; Beatriz Galan-Rodriguez
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

2.  Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

Authors:  Mahomi Kuroiwa; Gretchen L Snyder; Takahide Shuto; Atsuo Fukuda; Yuchio Yanagawa; David R Benavides; Angus C Nairn; James A Bibb; Paul Greengard; Akinori Nishi
Journal:  Psychopharmacology (Berl)       Date:  2011-08-11       Impact factor: 4.530

3.  NMDA antagonist MK801 recreates auditory electrophysiology disruption present in autism and other neurodevelopmental disorders.

Authors:  John A Saunders; Michael J Gandal; Timothy P Roberts; Steve J Siegel
Journal:  Behav Brain Res       Date:  2012-07-05       Impact factor: 3.332

Review 4.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 5.  Integrated approaches to understanding antipsychotic drug action at GPCRs.

Authors:  Nikhil M Urs; Peter J Nicholls; Marc G Caron
Journal:  Curr Opin Cell Biol       Date:  2013-12-14       Impact factor: 8.382

6.  Two quantitative trait loci for prepulse inhibition of startle identified on mouse chromosome 16 using chromosome substitution strains.

Authors:  Tracey L Petryshen; Andrew Kirby; Ronald P Hammer; Shaun Purcell; Sinead B O'Leary; Jonathan B Singer; Annie E Hill; Joseph H Nadeau; Mark J Daly; Pamela Sklar
Journal:  Genetics       Date:  2005-07-05       Impact factor: 4.562

7.  Disruption of dopamine neuron activity pattern regulation through selective expression of a human KCNN3 mutation.

Authors:  Marta E Soden; Graham L Jones; Christina A Sanford; Amanda S Chung; Ali D Güler; Charles Chavkin; Rafael Luján; Larry S Zweifel
Journal:  Neuron       Date:  2013-10-24       Impact factor: 17.173

Review 8.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

Review 9.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 10.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.